6,010 results on '"Acute Liver Failure"'
Search Results
2. TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
- Author
-
Ann & Robert H Lurie Children's Hospital of Chicago
- Published
- 2024
3. miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
- Published
- 2024
4. Outcomes Using MARS for Patients With ALF
- Published
- 2024
5. F573 for Injection for the Treatment of Liver Injury/Failure
- Published
- 2024
6. Plasma Exchange for Amanita Toxin-induced Acute Liver Failure (Amanita-Pex)
- Author
-
Stahl, Klaus Dr., PD Dr. Klaus Stahl, PD Dr. Richard Taubert, Dr. Bahar Nalbant
- Published
- 2024
7. Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China.
- Author
-
Yuan, Gaopin, Liu, Zhiyong, Chen, Zhixu, Zhang, Xiaohong, Zhang, Weifeng, and Chen, Dongmei
- Subjects
- *
METABOLIC disorders , *RESEARCH funding , *RETROSPECTIVE studies , *APPETITE , *LIVER diseases , *GENES , *AMINO acid metabolism disorders , *MEDICAL records , *ACQUISITION of data , *SEIZURES (Medicine) , *MOLECULAR biology , *GENETIC mutation , *GENOTYPES , *PHENOTYPES , *SLEEP stages , *LIVER failure , *LIVER transplantation , *SYMPTOMS - Abstract
Background: This study aimed to investigate the clinical and molecular genetic characteristics of ten children with ornithine carbamoyltransferase deficiency (OTCD) in southeastern China, as well as the correlation between the genotype and phenotype of OTCD. Methods: A retrospective analysis was performed on the clinical manifestations, laboratory testing, and genetic test findings of ten children with OTCD admitted between August 2015 and October 2021 at Quanzhou Maternity and Children's Hospital of Fujian Province in China. Results: Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure. In contrast, five patients (one boy and four girls) had late-onset gastrointestinal symptoms as the primary clinical manifestation, all presenting with hepatic impairment, and four with hepatic failure.Nine distinct variants of the OTC gene were identified, including two novel mutations: c.1033del(p.Y345Tfs*50) and c.167T > A(p.M56K). Of seven patients who died, five had early-onset disease despite active treatment. Three patients survived, and two of them underwent liver transplantation. Conclusions: The clinical manifestations of OTCD lack specificity. However, elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD. Genetic testing aids in more accurate diagnosis and prognosis assessment by clinicians. In addition, we identified two novel pathogenic variants and expand the mutational spectrum of the gene OTC, which may contribute to a better understanding of the clinical and genetic characteristics of OTCD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Association between serum alkaline phosphatase and clinical prognosis in patients with acute liver failure following cardiac arrest: a retrospective cohort study.
- Author
-
Xie, Yuequn, Lin, Liangen, Sun, Congcong, Chen, Linglong, and Lv, Wang
- Subjects
LOGISTIC regression analysis ,AKAIKE information criterion ,LIKELIHOOD ratio tests ,ALKALINE phosphatase ,INTENSIVE care units - Abstract
Background: Acute liver failure (ALF) following cardiac arrest (CA) poses a significant healthcare challenge, characterized by high morbidity and mortality rates. This study aims to assess the correlation between serum alkaline phosphatase (ALP) levels and poor outcomes in patients with ALF following CA. Methods: A retrospective analysis was conducted utilizing data from the Dryad digital repository. The primary outcomes examined were intensive care unit (ICU) mortality, hospital mortality, and unfavorable neurological outcome. Multivariable logistic regression analysis was employed to assess the relationship between serum ALP levels and clinical prognosis. The predictive value was evaluated using receiver operator characteristic (ROC) curve analysis. Two prediction models were developed, and model comparison was performed using the likelihood ratio test (LRT) and the Akaike Information Criterion (AIC). Results: A total of 194 patients were included in the analysis (72.2% male). Multivariate logistic regression analysis revealed that a one-standard deviation increase of ln-transformed ALP were independently associated with poorer prognosis: ICU mortality (odds ratios (OR) = 2.49, 95% confidence interval (CI) 1.31–4.74, P = 0.005), hospital mortality (OR = 2.21, 95% CI 1.18–4.16, P = 0.014), and unfavorable neurological outcome (OR = 2.40, 95% CI 1.25–4.60, P = 0.009). The area under the ROC curve for clinical prognosis was 0.644, 0.642, and 0.639, respectively. Additionally, LRT analyses indicated that the ALP-combined model exhibited better predictive efficacy than the model without ALP. Conclusions: Elevated serum ALP levels upon admission were significantly associated with poorer prognosis of ALF following CA, suggesting its potential as a valuable marker for predicting prognosis in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. CCL25 contributes to the pathogenesis of D‐Gal/LPS‐induced acute liver failure.
- Author
-
Sun, Fei, Wang, Jingwei, Ji, Xiangfen, Wang, Zhenli, Gao, Shuai, and Wang, Kai
- Subjects
- *
HEMATOXYLIN & eosin staining , *IMMUNOSTAINING , *LIVER cells , *CHEMOKINE receptors , *LIVER failure - Abstract
Background and Aim Methods Results Conclusion Acute liver failure (ALF) is a fatal clinical syndrome of severe hepatic dysfunction. Chemokines promote liver diseases by recruiting and activating immune cells. We aimed to investigate the role of C–C chemokine ligand 25 (CCL25) in ALF.An ALF mouse model induced by D‐galactosamine/lipopolysaccharide was evaluated through liver hematoxylin and eosin staining and serum transaminase and cytokine measurement. CCL25 expression in serum was analyzed by ELISA and in liver by immunohistochemical staining and western blot. C–C chemokine receptor 9 (CCR9)‐expressing cells in the liver were identified by immunofluorescence staining. The effects of anti‐CCL25 on ALF were evaluated in vivo. Cytokine expression and migration of CCL25‐stimulated RAW264.7 macrophages were studied. We also investigated the role of anti‐CCL25 and BMS‐345541, an NF‐κB signaling inhibitor, in vitro. NF‐κB activation was assessed via western blot, and p65 nuclear translocation was detected using cellular immunofluorescence.ALF mice showed severe histological damage and high serum levels of aminotransferase and inflammatory cytokines. Elevated CCL25 and NF‐κB activation was observed in vivo. CCR9 was expressed on macrophages in ALF mouse liver. ALF was suppressed after anti‐CCL25 treatment, with significant NF‐κB inhibition. In vitro, CCL25 induced strong migration and cytokine release in RAW264.7 macrophages, which were eliminated by anti‐CCL25 and BMS‐345541. Furthermore, the NF‐κB activation and p65 nuclear translocation induced by CCL25 were also inhibited by anti‐CCL25 and BMS‐345541.CCL25 contributes to ALF development by inducing macrophage‐mediated inflammation via activation of the NF‐κB signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Lebererkrankungen auf der Intensivstation.
- Author
-
Roedl, Kevin and Fuhrmann, Valentin
- Subjects
CRITICALLY ill patient care ,LIVER failure ,INTENSIVE care patients ,INTENSIVE care units ,LIVER diseases - Abstract
Copyright of Medizinische Klinik: Intensivmedizin & Notfallmedizin is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
11. Metabolic dysregulation‐triggered neutrophil extracellular traps exacerbate acute liver failure.
- Author
-
Zhang, Kangnan, Jia, Rongrong, Zhang, Qinghui, Xiang, Shihao, Wang, Na, and Xu, Ling
- Subjects
- *
REACTIVE oxygen species , *LIVER failure , *INTESTINAL abnormalities , *LIVER diseases , *DISEASE progression , *NEUTROPHILS - Abstract
Acute liver failure (ALF) is an acute liver disease with a high mortality rate in clinical practice, characterized histologically by extensive hepatocellular necrosis and massive neutrophil infiltration. However, the role of these abnormally infiltrating neutrophils during ALF development is unclear. Here, in an ALF mouse model, metabolites were identified that promote the formation of neutrophil extracellular traps (NETs) in the liver, subsequently influencing macrophage differentiation and disease progression. ALF occurs with abnormalities in hepatic and intestinal metabolites. Abnormal metabolites (LTD4 and glutathione) can directly, or indirectly via reactive oxygen species, promote NET formation of infiltrating neutrophils, which subsequently regulate macrophages in a pro‐inflammatory M1‐like state, inducing an amplification of the destructive effects of inflammation. Together, this study provides new insights into the role of NETs in the pathogenesis of ALF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical significance of transjugular liver biopsy in acute liver failure – a real-world analysis.
- Author
-
Nalbant, Bahar, Pape, Thorben, Schneider, Andrea, Seeliger, Benjamin, Schirmer, Paul, Heidrich, Benjamin, Taubert, Richard, Wedemeyer, Heiner, Lenzen, Henrike, and Stahl, Klaus
- Subjects
- *
LOGISTIC regression analysis , *LIVER biopsy , *RENAL replacement therapy , *LIVER failure , *THERAPEUTICS - Abstract
Background: Histopathological characterization obtained by transjugular liver biopsy (TJLB) may theoretically contribute to clarification of the exact aetiology of acute liver failure (ALF). It's unclear whether the histopathological information from TJLB, due to the small specimen size, significantly contributes to diagnosing ALF causes, guiding therapy decisions, or predicting overall prognosis. This retrospective study aimed to analyse safety and clinical significance of TJLB in patients with ALF. Methods: This retrospective, monocentric study investigated safety and efficacy of TJLB in patients with ALF over a ten-year period at a tertiary care transplant-center. The predictive value of various clinical and laboratory characteristics as well as histopathological findings obtained by TJLB on 28-day liver-transplant-free survival were evaluated by calculating uni- and multivariate Cox-proportional hazard regression models. Additional univariate logistic regression analyses were performed to explore the influence of degree of intrahepatic necrosis on the secondary endpoints intensive-care-unit (ICU) admission, need for endotracheal intubation, renal replacement therapy and high-urgency listing for LTX. Results: A total of 43 patients with ALF receiving TJLB were included into the study. In most cases (n = 39/43 cases) TJLB confirmed the initially already clinically presumed ALF aetiology and the therapeutic approach was unchanged by additional histological examination in the majority of patients (36/43 cases). However, in patients with a high suspicion for aetiologies potentially treatable by medical immunosuppression (e.g. AIH, GvHD), TJLB significantly influenced further treatment planning and/or adjustment. While the degree of intrahepatic necrosis showed significance in the univariate analysis (p = 0.04), it did not demonstrate a significant predictive effect on liver transplant-free survival in the multivariate analysis (p = 0.1). Only consecutive ICU admission was more likely with higher extent of intrahepatic necrosis (Odds ratio (OR) 1.04 (95% CI 1–1.08), p = 0.046). Conclusions: Performance of TJLB in ALF led to a change in suspected diagnosis and to a significant change in therapeutic measures only in those patients with a presumed high risk for aetiologies potentially responsive to immunosuppressive therapy. Clinical assessment alone was accurate enough, with additional histopathological examination adding no significant value, to predict overall prognosis of patients with ALF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Role of N-Acetyl Cysteine in Rodenticide poisoning.
- Author
-
Seelan S., Sheela Samini, karki, Arun, and Sivakumar, P.
- Subjects
- *
LIVER failure , *POISONS , *POISONING , *ACETYLCYSTEINE , *ORGANS (Anatomy) - Abstract
Background: N-acetyl cysteine (NAC) has been shown to be effective in the treatment of non-acetaminopheninduced acute liver failure. NAC has anti-inflammatory, inotropic, and vasodilatory properties. It has also shown to improve microcirculation and oxygen delivery in cases of liver failure. Rodenticide poisoning affects many vital organs in the body including liver thereby causing acute liver failure with a high mortality rate. Our study aimed to examine the clinical parameters of rodenticide poisoning patients and compare the severity of liver failure and the outcome after NAC treatment. Methods: From 2019 to 2021, a prospective study was conducted at Trichy SRM Hospital and Research Centre, Tamilnadu on patients who had a history of ingesting rat killer paste(RKP), a potent rodenticide. Patients who presented with RKP poisoning were administered NAC irrespective of the duration of poison intake, as an initial loading dose of 150 mg/kg infused in 200ml of 5% dextrose over 1 hour, followed by 50 mg/kg in 500ml of 5% dextrose over the next 4 hours, and then 100 mg/kg in 1000ml of 5% dextrose over the next 16 hours. The presence of liver injury or bleeding diathesis was assessed clinically and biochemically. Statistical analysis was done using chi-square test to compare the groups. Results: Among the 57 patients who were treated with NAC, 16 expired and 41 recovered. Development of Jaundice(p=0.02), hepatitis(p=0.028) and hypotension had highly significant (p < 0.01) correlation with the delay in time of presentation to the ICU which marks the time of NAC administration. Mortality was observed in these set of patients who had increased serum transaminases, bilirubin and prolonged PT & aPTT. Conclusion: In this study, patients who received NAC earlier had a higher percentage of complete recovery. Earlier administration use of NAC has prevented the emergence of negative outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
14. Nutritional management for acute liver failure.
- Author
-
Sasaki, Tokio, Kakisaka, Keisuke, Kuroda, Hidekatsu, and Matsumoto, Takayuki
- Subjects
- *
HEPATIC encephalopathy , *PROTEIN metabolism , *METABOLIC disorders , *LIVER failure , *ENTERAL feeding - Abstract
Acute liver failure (ALF) induces increased energy expenditure and disrupts the metabolism of essential nutrients. Hepatic encephalopathy is a complication of ALF with a poor prognosis and mainly involves the metabolic disturbance of amino acids in its pathogenesis. In this review, we discuss the nutritional management for ALF in consideration of the pathophysiology of ALF with respect to the impairment of hepatocyte function. It is known that enteral nutrition is recommended for patients with ALF, while parenteral nutrition is recommended for patients who cannot tolerate enteral nutrition. As ALF leads to a hypermetabolic state, the energy intake is recommended to cover 1.3 times the resting energy expenditure. Because of the high risk of hypoglycemia associated with disturbances in glucose metabolism, substantial glucose intake is recommended. Along with the deterioration of glucose metabolism, protein metabolism is also disrupted. As patients with ALF have increased systemic protein catabolism together with decreased protein synthesis, appropriate amounts of amino acids or protein under monitoring serum ammonia levels are recommended. In conclusion, nutritional management based on the understanding of nutritional pathophysiology is a pivotal therapeutic approach for patients with ALF. The approach should be individualized in the acute phase, the recovery phase, and the pretransplant phase. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Continuous renal replacement therapy and therapeutic plasma exchange in pediatric liver failure.
- Author
-
Jackson, Caroline, Carlin, Kristen, Blondet, Niviann, Jordan, Ian, Yalon, Larissa, Healey, Patrick J., Symons, Jordan M., and Menon, Shina
- Subjects
- *
PLASMA exchange (Therapeutics) , *RENAL replacement therapy , *LIVER failure , *HEPATIC encephalopathy , *CHILD patients , *BILIARY atresia - Abstract
Patients with acute liver failure (ALF) and acute on chronic liver failure (ACLF) have significant morbidity and mortality. They require extracorporeal blood purification modalities like continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) as a bridge to recovery or liver transplantation. Limited data are available on the outcomes of patients treated with these therapies. This is a retrospective single-center study of 23 patients from 2015 to 2022 with ALF/ACLF who underwent CRRT and TPE. We aimed to describe the clinical characteristics and outcomes of these patients. Median (IQR) age was 0.93 years (0.57, 9.88), range 16 days to 20 years. Ten (43%) had ALF and 13 (57%) ACLF. Most (n = 19, 82%) started CRRT for hyperammonemia and/or hepatic encephalopathy and all received TPE for refractory coagulopathy. CRRT was started at a median of 2 days from ICU admission, and TPE started on the same day in most. The liver transplant was done in 17 (74%), and 2 recovered native liver function. Four patients, all with ACLF, died prior to ICU discharge without a liver transplant. The median peak ammonia pre-CRRT was 131 µmol/L for the whole cohort. The mean (SD) drop in ammonia after 48 h of CRRT was 95.45 (43.72) µmol/L in those who survived and 69.50 (21.70) µmol/L in those who did not (p 0.26). Those who survived had 0 median co-morbidities compared to 2.5 in non-survivors (aOR (95% CI) for mortality risk of 2.5 (1.1–5.7), p 0.028). Conclusion: In this cohort of 23 pediatric patients with ALF or ACLF who received CRRT and TPE, 83% survived with a liver transplant or recovered with their native liver. Survival was worse in those who had ACLF and those with co-morbid conditions. What is Known: • Pediatric acute liver failure is associated with high mortality. • Patients may require extracorporeal liver assist therapies (like CRRT, TPE, MARS, SPAD) to bridge them over to a transplant or recovery of native liver function. What is New: • Standard volume plasma exhange has not been evaluated against high volume plasma exchange for ALF. • The role, dose, and duration of therapeutic plasma exchange in patients with acute on chronic liver failure is not well described. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Lactate as an early prognostic indicator in yellow phosphorus rodenticide-induced acute hepatic failure: a retrospective observational study in a tertiary care hospital.
- Author
-
Ramkumar, Anitha, Rajendran, Gunaseelan, Mahalingam, Sasikumar, Elanjeran, Rajkumar, and Gopalan, Mukhundhan
- Subjects
- *
RECEIVER operating characteristic curves , *LIVER failure , *BIOMARKERS , *LIVER transplantation , *RODENTICIDES , *PROTHROMBIN time - Abstract
Introduction: Acute hepatic failure due to yellow phosphorus rodenticide ingestion is often lethal. This study aimed to analyze demographic characteristics and prognostic indicators, focusing on hyperlactataemia as a potential early indicator of mortality in patients poisoned with yellow phosphorus rodenticide. Materials and methods: This was a retrospective study of 96 patients poisoned with a yellow phosphorus-containing rodenticide (Ratol paste, which contains 3% yellow phosphorus). We examined demographic details, clinical symptoms, and biochemical markers to identify prognostic indicators. Results: Demographics were similar among survivors and non-survivors. Mortality (36.5%) correlated with a higher ingested dose and treatment delays, with a mean (±SD) of 5.26 ± 2.2 survival days among those who died. Symptoms, including gastrointestinal and neurological features, typically appeared 48 h after ingestion. Non-survivors developed increased aminotransferase activities (74.3%), prolonged prothrombin time (65.7%), and hyperbilirubinaemia (65.7%) during hospitalization, significantly more commonly compared to survivors (P < 0.0001). Hyperlactataemia (lactate concentration >2 mmol/L) was present in 97.1% of non-survivors, with increased serial lactate concentrations observed in 88.6%. The median (interquartile range) admission lactate concentration among non-survivors was 4.6 mmol/L (3.36–7.53 mmol/L), and their peak median (interquartile range) lactate concentration was 6.1 mmol/L (8.74–10.6 mmol/L). In non-survivors, an increased lactate concentration preceded increased aminotransferase activities and prolonged prothrombin time. Logistic regression and receiver operating characteristic curve analysis confirmed that a 24 h lactate concentration ≥2.67 mmol/L predicted death with 94.3% sensitivity and 91.8% specificity. Discussion: The majority of patients who ingest yellow phosphorus remain asymptomatic initially and typically present to hospital following the onset of gastrointestinal symptoms, usually a day later. As progression to death occurs within a week of yellow phosphorus ingestion in most cases, determining prognosis as early as possible enables swift referral to a liver transplant centre. Based on our study, a 24 h lactate concentration ≥2.67 mmol/L appears to be an early prognostic indicator of death. In another study, a lactate concentration >5.8 mmol/L was found to be a poor prognostic indicator. Conclusions: Hyperlactataemia on admission and increased serial lactate concentrations appear to be early poor prognostic signs in patients with yellow phosphorus-induced liver failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis.
- Author
-
Fawzy, Aly, Sutton, Harry, Vandriel, Shannon M., Sonnenberg, Mikayla, and Kamath, Binita M.
- Subjects
- *
AUTOIMMUNE hepatitis , *LIVER failure , *PEDIATRICS , *LIVER transplantation , *DATABASES - Abstract
Background and Aims: Autoimmune hepatitis (AIH) in children presenting in acute liver failure (ALF) can be fatal and often requires liver transplantation (LTx). This individual patient data meta‐analysis (IPD) aims to examine management and outcomes of this population, given the lack of large cohort studies on paediatric AIH first presenting as ALF (AIH‐ALF). Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta‐Analyses of IPD statement using PubMed and Excerpta Medica dataBASE, and included English studies published between 2000 and 2020. The study included patients under 21 years of age, diagnosed with type 1 or 2 AIH and presenting with ALF. Data extracted included clinical and biochemical characteristics, interventions, and outcomes. Results: Three hundred and thirty eligible patients from 61 studies were identified, with an additional five patients from our institution. The majority were female (66.8%), with a median age of 10. Overall, 59.7% achieved native liver survival (NLS), 35% underwent LTx, and 5% died before LTx. The use of corticosteroids with non‐steroid immunomodulators increased the likelihood of NLS by 2.5‐fold compared to corticosteroids alone. AIH‐1 was associated with 3.3‐fold odds for NLS, compared to AIH‐2. However, on multivariate analysis, only AIH‐1 was identified as an independent predictor for NLS (OR 3.8 [95% CI 1.03–14.2], p =.04). Conclusion: While corticosteroids and non‐steroid immunomodulators treatment may offer enhanced probability of achieving NLS, treatment regimens for AIH‐ALF may need to consider patient‐specific factors, especially AIH type. This highlights the potential for NLS in AIH‐ALF and suggest a need to identify biomarkers which predict the need for combination immunosuppression to avoid LTx. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Macrophage activation markers are associated with infection and mortality in patients with acute liver failure.
- Author
-
Cavazza, Anna, Triantafyllou, Evangelos, Savoldelli, Roberto, Mujib, Salma, Jerome, Ellen, Trovato, Francesca M., Artru, Florent, Sheth, Roosey, Huang, Xiao Hong, Ma, Yun, Dazzi, Francesco, Pirani, Tasneem, Antoniades, Charalambos G., Lee, William M., McPhail, Mark J., and Karvellas, Constantine J.
- Subjects
- *
LIVER failure , *MACROPHAGE activation , *ENZYME-linked immunosorbent assay , *MORTALITY , *CD14 antigen - Abstract
Background and Aims: Acute liver failure is a multisystem disorder with a high mortality and frequent need for emergency liver transplantation. Following massive innate immune system activation, soluble markers of macrophage activation are released during liver damage and their association with disease severity and prognosis requires exploration. Methods: Patients ALF from the United States Acute Liver Failure Study Group (USALFSG, n = 224) and King's College Hospital (n = 40) together with healthy controls (HC, n = 50) were recruited. Serum from early (Days 1–3) and late (>Day 3) time points were analysed for MAMs by enzyme‐linked immunosorbent assay correlated to markers of illness severity and 21‐day spontaneous survival. Surface expression phenotyping was performed via Flow Cytometry on CD14+ monocytes. Results: All MAMs serum concentrations were significantly higher in ALF compared to controls (p <.0001). sCD206 concentration was higher in early and late stages of the disease in patients with bacteraemia (p =.002) and infection in general (p =.006). In MELD‐adjusted multivariate modelling, sCD206 and sCD163 were independently associated with mortality. CD14+ monocyte expression of CD206 (p <.001) was higher in patients with ALF compared with controls and correlated with SOFA score (p =.018). sCD206 was independently validated as a predictor of infection in an external cohort. Conclusions: sCD206 is increased in serum of ALF patients with infections and poor outcome and is upregulated on CD14+ monocytes. Later measurements of sCD163 and sCD206 during the evolution of ALF have potential as mechanistic predictors of mortality. sCD206 should be explored as a biomarker of sepsis and mortality in ALF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. A Rare Cause of Acute Liver Failure.
- Author
-
Gibbens, Ying, Lake, John, and Lim, Nicholas
- Published
- 2024
- Full Text
- View/download PDF
20. Bioinspired menstrual blood‐derived stem cells‐conditioned medium/polymersome nanoparticles for the treatment of carbon tetrachloride‐induced acute liver failure in mice.
- Author
-
Li, Zuhong, Li, Qian, Ouyang, Xiaoxi, Tang, Shima, Liu, Qiuhong, Zhang, Yaqi, Zhang, Yanhong, Yu, Xiaopeng, Zhu, Danhua, Mu, Ying, and Li, Lanjuan
- Subjects
POLYMERSOMES ,CARBON tetrachloride ,LIVER failure ,NANOPARTICLES ,STEM cell treatment ,BLOCK copolymers ,LIVER transplantation - Abstract
Acute liver failure is a life‐threatening syndrome, for which liver transplantation is presently the most effective treatment. Unfortunately, such treatment is extremely limited by a shortage of donor organs. Stem cell therapy offers a promising treatment strategy for acute liver failure. Yet, therapeutic efficacy and potential are hampered by administration route and safety concerns. In this work, we fabricated menstrual blood‐derived stem cells‐conditioned medium/polymersome hybrid nanoparticles that were self‐assembled from amphiphilic block copolymers via the direct hydration method and encapsulated therapeutic bioactive factors within the aqueous core of vesicles. The merit of vesicular architecture enabled the loading capacity of distinct proteins and the maintenance of biological activity. These hybrid nanoparticles can be steadily taken up into cytoplasm and promote hepatocyte proliferation in vitro. Prolonged in vivo circulation time brought higher accumulation in livers. The therapeutic nanoparticles alleviated hepatic injury and promoted liver recovery in mice with carbon tetrachloride‐induced liver failure. Considering the feasibility and benefit of the hybrid nanoparticle therapy, it provided a potential strategy to treat acute liver failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Pathophysiological features of acute liver failure caused by cholestasis.
- Author
-
Kolosovych, I. V., Hanol, I. V., and Nesteruk, Y. O.
- Subjects
- *
CHRONIC active hepatitis , *LIVER failure , *OBSTRUCTIVE jaundice , *SYSTEMIC inflammatory response syndrome , *HEPATITIS D virus , *AUTOIMMUNE hepatitis ,BILIARY tract cancer - Abstract
Acute liver failure is a syndrome that occurs in 20-59% of patients with liver pathology and is one of the main causes of death in 40% of patients with mechanical jaundice of benign origin and in more than 70% of cases of tumor obstruction of the biliary tract and cancer of caput pancreas. In most cases, the syndrome is a consequence of acute liver damage (viral or drug-induced). Still, it can occur with longterm obstructive jaundice, be the first manifestation of Wilson's disease, autoimmune chronic hepatitis, or superinfection of the hepatitis D virus against the background of chronic hepatitis B. The aim of the work was to study the pathophysiological features of the development of acute liver failure in patients with bile outflow disorders. The pathogenesis of acute liver failure caused by cholestasis is based on the damage and death of hepatocytes due to impaired blood circulation in the liver, as well as the toxic effect on the parenchyma of both the etiological factors themselves and their metabolites. The first week from the onset of symptoms is very important and usually accompanied by a systemic inflammatory response syndrome with significant consequences. At the same time, the main factors influencing the results of treatment of patients at different points in time are the combination of the critical functional reserve of the liver and the nature and severity of liver damage. In the case of the development of a systemic inflammatory response syndrome, there is a further increase in inflammation, which has a systemic nature and leads to the failure of other organs. Under these circumstances, understanding the pathophysiological features of the course of acute liver failure makes it possible to carry out the necessary diagnostic measures on time and offer appropriate therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
22. M2-type macrophage membrane-mediated delivery of Carvedilol nanocomplex for acute liver failure treatment and remodeling inflammatory microenvironment.
- Author
-
Shang, Mingge, Zhang, Yaohui, Qian, Junjie, Wang, Wenchao, Yu, Xizhi, Huang, Jiacheng, Zhou, Lin, and Zheng, Shusen
- Subjects
LIVER failure ,CARVEDILOL ,TREATMENT failure ,MACROPHAGES ,RETICULO-endothelial system ,SUMATRIPTAN ,BIOMIMETIC materials - Abstract
Interactions of hepatic macrophages with local inflammatory microenvironment is the key factor promoting the development of acute liver failure (ALF). Hence, reprogramming pro-inflammatory M1 into anti-inflammatory M2 phenotype may offer a promising strategy for treating ALF by targeting inflammation. Our group found Carvedilol possessed potential anti-inflammatory property previously, which had been scarcely reported in ALF. We present a synergy strategy to induce macrophages into the phenotype M2-type anti-inflammatory macrophages with interleukin-4 (IL-4) and IL-10 at first. Then Carvedilol is loaded on the macrophage membrane-camouflaged biomimetic nano-platform (termed as M2M@CNP) to evade reticuloendothelial system (RES) and afford Carvedilol delivery to the inflammatory environment with overproduced reactive oxygen species (ROS), further prolonging its circulation and accumulation. Sustainably released Carvedilol produced anti-inflammatory, antioxidant and anti-apoptosis effects, combining local M2-type cell membranes (M2-CM) inhibited pro-inflammatory cytokines and ROS levels, which in turn promoted and amplified M1 to M2 phenotype polarization efficiency. This study offers new insights into the rational design of biomimetic nanosystems for safe and effective ALF therapy to accelerate the clinical translation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Genetic aetiologies of acute liver failure.
- Author
-
Hegarty, Robert and Thompson, Richard J.
- Abstract
Acute liver failure (ALF) is a rare, rapidly evolving, clinical syndrome with devastating consequences where definitive treatment is by emergency liver transplantation. Establishing a diagnosis can be challenging and, historically, the cause of ALF was unidentified in up to half of children. However, recent technological and clinical advances in genomic medicine have led to an increasing proportion being diagnosed with monogenic aetiologies of ALF. The conditions encountered include a diverse group of inherited metabolic disorders each with prognostic and treatment implications. Often these disorders are clinically indistinguishable and may even mimic disorders of immune regulation or red cell disorders. Rapid genomic sequencing for children with ALF is, therefore, a key component in the diagnostic work up today. This review focuses on the monogenic aetiologies of ALF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. No Significant Beneficial Effects of Intravenous N-Acetylcysteine on Patient Outcome in Non-Paracetamol Acute Liver Failure: A Meta-Analysis of Randomized Controlled Trials.
- Author
-
Orban, Carmen, Agapie, Mihaela, Bratu, Angelica, Jafal, Mugurel, Duțu, Mădălina, and Popescu, Mihai
- Subjects
LENGTH of stay in hospitals ,LIVER failure ,CHILD patients ,OVERALL survival ,RANDOMIZED controlled trials - Abstract
Acute liver failure is a life-threatening organ dysfunction with systemic organ involvement and is associated with significant mortality and morbidity unless specific management is undertaken. This meta-analysis aimed to assess the effects of intravenous N-acetylcysteine (NAC) on mortality and the length of hospital stay in patients with non-acetaminophen acute liver failure. Two hundred sixty-six studies from four databases were screened, and four randomized control trials were included in the final analysis. Our results could not demonstrate increased overall survival (OR 0.70, 95% CI [0.34, 1.44], p = 0.33) or transplant-free survival (OR 0.90, 95% CI [0.25, 3.28], p = 0.87) in patients treated with intravenous NAC. We observed an increased overall survival in adult patients treated with NAC (OR 0.59, 95% CI [0.35, 0.99], p = 0.05) compared to pediatric patients, but whether this is attributed to the age group or higher intravenous dose administered remains unclear. We did not observe a decreased length of stay in NAC-treated patients (OR −5.70, 95% CI [−12.44, 1.05], p = 0.10). In conclusion, our meta-analysis could not demonstrate any significant benefits on overall and transplant-free patient survival in non-acetaminophen ALF. Future research should also focus on specific etiologies of ALF that may benefit most from the use of NAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Association between serum alkaline phosphatase and clinical prognosis in patients with acute liver failure following cardiac arrest: a retrospective cohort study
- Author
-
Yuequn Xie, Liangen Lin, Congcong Sun, Linglong Chen, and Wang Lv
- Subjects
Alkaline phosphatase ,Acute liver failure ,Clinical prognosis ,Risk factor ,Cardiac arrest ,Medicine - Abstract
Abstract Background Acute liver failure (ALF) following cardiac arrest (CA) poses a significant healthcare challenge, characterized by high morbidity and mortality rates. This study aims to assess the correlation between serum alkaline phosphatase (ALP) levels and poor outcomes in patients with ALF following CA. Methods A retrospective analysis was conducted utilizing data from the Dryad digital repository. The primary outcomes examined were intensive care unit (ICU) mortality, hospital mortality, and unfavorable neurological outcome. Multivariable logistic regression analysis was employed to assess the relationship between serum ALP levels and clinical prognosis. The predictive value was evaluated using receiver operator characteristic (ROC) curve analysis. Two prediction models were developed, and model comparison was performed using the likelihood ratio test (LRT) and the Akaike Information Criterion (AIC). Results A total of 194 patients were included in the analysis (72.2% male). Multivariate logistic regression analysis revealed that a one-standard deviation increase of ln-transformed ALP were independently associated with poorer prognosis: ICU mortality (odds ratios (OR) = 2.49, 95% confidence interval (CI) 1.31–4.74, P = 0.005), hospital mortality (OR = 2.21, 95% CI 1.18–4.16, P = 0.014), and unfavorable neurological outcome (OR = 2.40, 95% CI 1.25–4.60, P = 0.009). The area under the ROC curve for clinical prognosis was 0.644, 0.642, and 0.639, respectively. Additionally, LRT analyses indicated that the ALP-combined model exhibited better predictive efficacy than the model without ALP. Conclusions Elevated serum ALP levels upon admission were significantly associated with poorer prognosis of ALF following CA, suggesting its potential as a valuable marker for predicting prognosis in this patient population.
- Published
- 2024
- Full Text
- View/download PDF
26. Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China
- Author
-
Gaopin Yuan, Zhiyong Liu, Zhixu Chen, Xiaohong Zhang, Weifeng Zhang, and Dongmei Chen
- Subjects
Ornithine transcarbamylase deficiency ,Hyperammonemia ,Gene mutation ,Urea cycle disorders ,Acute liver failure ,Pediatrics ,RJ1-570 - Abstract
Abstract Background This study aimed to investigate the clinical and molecular genetic characteristics of ten children with ornithine carbamoyltransferase deficiency (OTCD) in southeastern China, as well as the correlation between the genotype and phenotype of OTCD. Methods A retrospective analysis was performed on the clinical manifestations, laboratory testing, and genetic test findings of ten children with OTCD admitted between August 2015 and October 2021 at Quanzhou Maternity and Children’s Hospital of Fujian Province in China. Results Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure. In contrast, five patients (one boy and four girls) had late-onset gastrointestinal symptoms as the primary clinical manifestation, all presenting with hepatic impairment, and four with hepatic failure.Nine distinct variants of the OTC gene were identified, including two novel mutations: c.1033del(p.Y345Tfs*50) and c.167T > A(p.M56K). Of seven patients who died, five had early-onset disease despite active treatment. Three patients survived, and two of them underwent liver transplantation. Conclusions The clinical manifestations of OTCD lack specificity. However, elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD. Genetic testing aids in more accurate diagnosis and prognosis assessment by clinicians. In addition, we identified two novel pathogenic variants and expand the mutational spectrum of the gene OTC, which may contribute to a better understanding of the clinical and genetic characteristics of OTCD patients.
- Published
- 2024
- Full Text
- View/download PDF
27. Acute Autoimmune Hepatitis with Amyopathic Dermatomyositis: “A Diagnostic and a Therapeutic Dilemma” : A Case Report
- Author
-
K. Maddumabandara, I. Kothalawala, P. Kaththota, and S. Bowattage
- Subjects
acute autoimmune hepatitis ,amyopathic dermatomyositis ,acute liver failure ,plasma exchange ,Medicine - Abstract
Autoimmune hepatitis (AIH) is a rare, immune-mediated inflammatory liver disorder, while its acute form has a spectrum of clinical manifestations including acute-icteric AIH, acute severe AIH (AS-AIH) and AS-AIH with acute liver failure (ALF) (1). A subset of patients with dermatomyositis (DM) presents with characteristic skin findings but without muscle involvement, termed clinically amyopathic dermatomyositis (CADM). This subgroup includes patients with amyopathic DM(AMD), who are devoid of all clinical and laboratory findings of muscle involvement (2). We report a case of a previously healthy 54-year-old woman who presented with acute icteric AIH and features of AMD, rapidly progressing to AS-AIH with ALF and the diagnostic and therapeutic challenges encountered while managing the patient.
- Published
- 2024
- Full Text
- View/download PDF
28. Thyroid storm with acute liver failure and disseminated intravascular coagulation- lessons in diagnosis and treatment
- Author
-
Manudi Vidanapathirana and Dilushi Wijayaratne
- Subjects
Thyroid storm ,Acute liver failure ,Disseminated intravascular coagulation ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Thyroid storm is a medical emergency with a high mortality rate. Acute liver failure (ALF) and disseminated intravascular coagulation (DIC) are rarely reported with thyroid storm, and their occurrence is unrelated to the degree of free circulating thyroxine. We present the case of a 41-year-old Sri Lankan female, with a fatal case of thyroid storm. She initially presented with palpitations and heat intolerance, and subsequently developed acute liver failure with hepatic encephalopathy and coagulopathy. There was hypoglycemia and resistant lactic acidosis consequent to the liver failure. The clinical course progressed to DIC and she eventually succumbed to the illness. Treatment comprised the standard management of thyroid storm. This case report highlights the importance of bearing ALF and DIC in mind as complications of thyroid storm, outlines their pathophysiology, and uses pathophysiological mechanisms to justify, evolving extracorporeal therapeutic strategies for resistant cases.
- Published
- 2024
- Full Text
- View/download PDF
29. Clinical significance of transjugular liver biopsy in acute liver failure – a real-world analysis
- Author
-
Bahar Nalbant, Thorben Pape, Andrea Schneider, Benjamin Seeliger, Paul Schirmer, Benjamin Heidrich, Richard Taubert, Heiner Wedemeyer, Henrike Lenzen, and Klaus Stahl
- Subjects
Acute liver failure ,Transjugular liver biopsy ,Liver biopsy ,Liver transplant free survival ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Histopathological characterization obtained by transjugular liver biopsy (TJLB) may theoretically contribute to clarification of the exact aetiology of acute liver failure (ALF). It's unclear whether the histopathological information from TJLB, due to the small specimen size, significantly contributes to diagnosing ALF causes, guiding therapy decisions, or predicting overall prognosis. This retrospective study aimed to analyse safety and clinical significance of TJLB in patients with ALF. Methods This retrospective, monocentric study investigated safety and efficacy of TJLB in patients with ALF over a ten-year period at a tertiary care transplant-center. The predictive value of various clinical and laboratory characteristics as well as histopathological findings obtained by TJLB on 28-day liver-transplant-free survival were evaluated by calculating uni- and multivariate Cox-proportional hazard regression models. Additional univariate logistic regression analyses were performed to explore the influence of degree of intrahepatic necrosis on the secondary endpoints intensive-care-unit (ICU) admission, need for endotracheal intubation, renal replacement therapy and high-urgency listing for LTX. Results A total of 43 patients with ALF receiving TJLB were included into the study. In most cases (n = 39/43 cases) TJLB confirmed the initially already clinically presumed ALF aetiology and the therapeutic approach was unchanged by additional histological examination in the majority of patients (36/43 cases). However, in patients with a high suspicion for aetiologies potentially treatable by medical immunosuppression (e.g. AIH, GvHD), TJLB significantly influenced further treatment planning and/or adjustment. While the degree of intrahepatic necrosis showed significance in the univariate analysis (p = 0.04), it did not demonstrate a significant predictive effect on liver transplant-free survival in the multivariate analysis (p = 0.1). Only consecutive ICU admission was more likely with higher extent of intrahepatic necrosis (Odds ratio (OR) 1.04 (95% CI 1–1.08), p = 0.046). Conclusions Performance of TJLB in ALF led to a change in suspected diagnosis and to a significant change in therapeutic measures only in those patients with a presumed high risk for aetiologies potentially responsive to immunosuppressive therapy. Clinical assessment alone was accurate enough, with additional histopathological examination adding no significant value, to predict overall prognosis of patients with ALF.
- Published
- 2024
- Full Text
- View/download PDF
30. Successful maintenance therapy with tocilizumab for severe acute liver failure associated with adult-onset still’s disease
- Author
-
Koji Suzuki, Mitsuhiro Akiyama, Yukie Nakadai, Shingo Usui, and Yuko Kaneko
- Subjects
Adult-onset still’s disease ,acute liver failure ,tocilizumab ,cyclosporine ,immunosuppressive therapy ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Elevated liver enzymes are commonly observed among adult-onset Still’s disease (AOSD), but severe acute liver failure is extremely rare. Although severe acute liver failure associated with AOSD poses a life-threatening condition, the appropriate treatment is unclear. Some case reports have demonstrated the efficacy of high-dose prednisolone (PSL) and cyclosporin A (CyA), although the adverse effects of CyA led certain patients to cease its use. Therefore, an alternative treatment option is crucial, and thus far, there have been no reports of tocilizumab (TCZ) being used for this severe phenotype. Here, we report the first case of successful treatment using TCZ as maintenance therapy for severe ALF associated with AOSD. Following initial treatment with high-dose PSL and CyA, our case was switched to TCZ due to CyA-related side effects including alopecia and tremors. Our case highlights TCZ as a potential option for maintenance therapy of this severe condition.
- Published
- 2024
- Full Text
- View/download PDF
31. Falla hepática aguda: manejo actual y pronóstico
- Author
-
L.M. Martínez-Martínez, G. Rosales-Sotomayor, E.A. Jasso-Baltazar, J.A. Torres-Díaz, D. Aguirre-Villarreal, I. Hurtado-Díaz de León, V.M. Páez-Zayas, A. Sánchez-Cedillo, S.E. Martínez-Vázquez, H.N. Tadeo-Espinoza, J.P. Guerrero-Cabrera, M. García-Alanis, and I. García-Juárez
- Subjects
Acute liver failure ,Acute liver injury ,Hepatic encephalopathy ,Renal replacement therapy ,Liver transplantation ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Resumen: La falla hepática aguda es un síndrome poco común pero grave, con una incidencia de aproximadamente 2,000 a 3,000 casos por año en América del Norte. Su fisiopatología y curso clínico varían según la causa del daño hepático primario, y puede llevar a una alta morbimortalidad o necesidad de trasplante hepático, a pesar de las terapias disponibles. Este síndrome involucra una activación excesiva del sistema inmunológico con daño en otros órganos, lo que contribuye a su alta tasa de mortalidad. La definición más aceptada incluye daño hepático con encefalopatía hepática y coagulopatía en las últimas 26 semanas en un paciente sin enfermedad hepática previa. Las principales causas son intoxicación por paracetamol, hepatitis viral, lesión hepática inducida por drogas, entre otras. Es crucial identificar la causa, ya que influye en el pronóstico y tratamiento. La supervivencia ha mejorado con medidas de soporte, terapia intensiva, prevención de complicaciones y el uso de medicamentos como la N-acetilcisteína. El trasplante hepático es una opción curativa para casos no respondedores al tratamiento médico, pero la evaluación adecuada del momento para el trasplante es crucial para mejorar los resultados. Factores como la edad del paciente, la causa subyacente y la gravedad de las fallas orgánicas influyen en los resultados y la supervivencia postrasplante. Abstract: Acute liver failure is a rare but serious syndrome, with an incidence of approximately 2,000 to 3,000 cases per year in North America. Its pathophysiology and clinical course vary, depending on the cause of the primary liver injury, and can lead to high morbidity and mortality or the need for liver transplantation, despite available therapies. This syndrome involves excessive activation of the immune system, with damage in other organs, contributing to its high mortality rate. The most accepted definition includes liver injury with hepatic encephalopathy and coagulopathy within the past 26 weeks in a patient with no previous liver disease. The main causes are paracetamol poisoning, viral hepatitis, and drug-induced liver injury, among others. Identifying the cause is crucial, given that it influences prognosis and treatment. Survival has improved with supportive measures, intensive therapy, complication prevention, and the use of medications, such as N-acetylcysteine. Liver transplantation is a curative option for nonresponders to medical treatment, but adequate evaluation of transplantation timing is vital for improving results. Factors such as patient age, underlying cause, and severity of organ failure influence the post-transplant outcomes and survival.
- Published
- 2024
- Full Text
- View/download PDF
32. Liver
- Author
-
Anand, A. C., Choudhuri, Gourdas, editor, Anand, Anil C, editor, and Piramanayagam, P, editor
- Published
- 2024
- Full Text
- View/download PDF
33. Fluid Management in Liver Failure
- Author
-
Mekeirele, Michaël, Wilmer, Alexander, Malbrain, Manu L.N.G., editor, Wong, Adrian, editor, Nasa, Prashant, editor, and Ghosh, Supradip, editor
- Published
- 2024
- Full Text
- View/download PDF
34. Longitudinal Study of Mitochondrial Hepatopathies (MITOHEP)
- Author
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and University of Michigan
- Published
- 2023
35. The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure
- Author
-
Yang Yang, Head of Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University
- Published
- 2023
36. Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy
- Published
- 2023
37. Death from bongkrekic acid toxicity: first report in North America.
- Author
-
Rivera Blanco, Liz Eneida, Kuai, David, Titelbaum, Nicholas, Fiza, Babar, Reehl, David, Hassan, Zakaa, Dbouk, Nader, Krotulski, Alex J., Logan, Barry K., Walton, Sara E., Liu, Irene, Yu, Michael, and Carpenter, Joseph
- Subjects
- *
DIGESTIVE system diseases , *FOOD poisoning , *MULTIPLE organ failure , *THERAPEUTICS , *FATIGUE (Physiology) - Published
- 2024
- Full Text
- View/download PDF
38. Severe acute liver disease in adults: Contemporary role of histopathology.
- Author
-
Clouston, Andrew D, Gouw, Annette S H, Tiniakos, Dina, Bedossa, Pierre, Brunt, Elizabeth M, Callea, Francesco, Dienes, Hans‐Peter, Goodman, Zachary D, Hubscher, Stefan G, Kakar, Sanjay, Kleiner, David E, Lackner, Carolin, Park, Young N, Roberts, Eve A, Schirmacher, Peter, Terracciano, Luigi, Torbenson, Michael, Wanless, Ian R, Zen, Yoh, and Burt, Alastair D
- Abstract
Liver biopsies have consistently contributed to our understanding of the pathogenesis and aetiologies of acute liver disease. As other diagnostic modalities have been developed and refined, the role of biopsy in the management of patients with acute liver failure (ALF), acute‐on‐chronic liver failure (ACLF) and acute hepatitis, including acute liver injury (ALI), has changed. Liver biopsy remains particularly valuable when first‐line diagnostic algorithms fail to determine aetiology. Despite not being identified as a mandatory diagnostic tool in recent clinical guidelines for the management of ALF or ACLF, many centres continue to undertake biopsies given the relative safety of transjugular biopsy in this setting. Several studies have demonstrated that liver biopsy can provide prognostic information, particularly in the context of so‐called indeterminate hepatitis, and is extremely useful in excluding conditions such as metastatic tumours that would preclude transplantation. In addition, its widespread use of percutaneous biopsies in cases of less severe acute liver injury, for example in the establishment of a diagnosis of acute presentation of autoimmune hepatitis or confirmation of a probable or definite drug‐induced liver injury (DILI), has meant that many centres have seen a shift in the ratio of specimens they are receiving from patients with chronic to acute liver disease. Histopathologists therefore need to be equipped to deal with these challenging specimens. This overview provides an insight into the contemporary role of biopsies (as well as explant and autopsy material) in diagnosing acute liver disease. It outlines up‐to‐date clinical definitions of liver injury and considers recent recommendations for the diagnosis of AIH and drug‐induced, autoimmune‐like hepatitis (DI‐AIH). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Intraoperative kidney replacement therapy in acute liver failure.
- Author
-
Henderson, Daniel, Gupta, Anish, Menon, Shina, and Deep, Akash
- Subjects
- *
KIDNEY failure , *ACUTE diseases , *PATIENT safety , *MULTIPLE organ failure , *HEMODIALYSIS , *CATASTROPHIC illness , *INTRAOPERATIVE care , *PEDIATRICS , *LIVER failure , *LIVER transplantation , *DISEASE complications , *CHILDREN - Abstract
Paediatric acute liver failure (PALF) is often characterised by its rapidity of onset and potential for significant morbidity and even mortality. Patients often develop multiorgan dysfunction/failure, including severe acute kidney injury (AKI). Whilst the management of PALF focuses on complications of hepatic dysfunction, the associated kidney impairment can significantly affect patient outcomes. Severe AKI requiring continuous kidney replacement therapy (CKRT) is a common complication of both PALF and liver transplantation. In both scenarios, the need for CKRT is a poor prognostic indicator. In adults, AKI has been shown to complicate ALF in 25–50% of cases. In PALF, the incidence of AKI is often higher compared to other critically ill paediatric ICU populations, with reports of up to 40% in some observational studies. Furthermore, those presenting with AKI regularly have a more severe grade of PALF at presentation. Observational studies in the paediatric population corroborate this, though data are not as robust—mainly reflecting single-centre cohorts. Perioperative benefits of CKRT include helping to clear water-soluble toxins such as ammonia, balancing electrolytes, preventing fluid overload, and managing raised intracranial pressure. As liver transplantation often takes 6–10 h, it is proposed that these benefits could be extended to the intraoperative period, avoiding any hiatus. Intraoperative CKRT (IoCKRT) has been shown to be practicable, safe and may help sicker recipients tolerate the operation with outcomes analogous with less ill patients not requiring IoCKRT. Here, we provide a comprehensive guide describing the rationale, practicalities, and current evidence base surrounding IoCKRT during transplantation in the paediatric population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Early onset and liver failure indicating poor prognosis of infant liver failure syndrome type 1
- Author
-
Shu-Yuan Li, Jia-Yan Feng, Zhong-Die Li, and Teng Liu
- Subjects
Acute liver failure ,Genotype ,Survival analysis ,LARS1 ,Leucyl-tRNA synthase 1 ,Medicine - Abstract
Abstract Background Infantile liver failure syndrome type 1 (ILFS1, OMIM #615,438), caused by leucyl-tRNA synthase 1 (LARS1, OMIM *151,350) deficiency, is a rare autosomal-recessive disorder. The clinical manifestations, molecular-genetic features, and prognosis of LARS1 disease remain largely elusive. Methods Three new instances of ILFS1 with confirmed variants in LARS1, encoding LARS1, were identified. Disease characteristics were summarized together with those of 33 reported cases. Kaplan-Meier analysis was performed to assess prognostic factors in ILFS1 patients. Results The 3 new ILFS1 patients harbored 6 novel variants in LARS1. Among the 36 known patients, 12 died or underwent liver transplantation. The main clinical features of ILFS1 were intrauterine growth restriction (31/32 patients in whom this finding was specifically described), failure to thrive (30/31), hypoalbuminemia (32/32), microcytic anemia (32/33), acute liver failure (24/34), neurodevelopmental delay (25/30), seizures (22/29), and muscular hypotonia (13/27). No significant correlations were observed between genotype and either presence of liver failure or clinical severity of disease. Kaplan-Meier analysis indicated that age of onset
- Published
- 2024
- Full Text
- View/download PDF
41. Mesenchymal stromal cell-derived extracellular vesicles therapy openings new translational challenges in immunomodulating acute liver inflammation
- Author
-
Alexandre Sitbon, Pierre-Romain Delmotte, Valéria Pistorio, Sébastien Halter, Jérémy Gallet, Jérémie Gautheron, and Antoine Monsel
- Subjects
Mesenchymal stromal cells ,Exosomes ,Extracellular vesicles ,Acute liver failure ,Acute-on-chronic liver failure ,Ischemia–reperfusion injury ,Medicine - Abstract
Abstract Inflammation plays a critical role in conditions such as acute liver failure, acute-on-chronic liver failure, and ischemia–reperfusion-induced liver injury. Various pathogenic pathways contribute to liver inflammation, involving inflammatory polarization of macrophages and Küpffer cells, neutrophil infiltration, dysregulation of T cell subsets, oxidative stress, and activation of hepatic stellate cells. While mesenchymal stromal cells (MSCs) have demonstrated beneficial properties, their clinical translation is limited by their cellular nature. However, MSC-derived extracellular vesicles (MSC-EVs) have emerged as a promising cell-free therapeutic approach for immunomodulation. MSC-EVs naturally mirror their parental cell properties, overcoming the limitations associated with the use of MSCs. In vitro and in vivo preclinical studies have demonstrated that MSC-EVs replicate the beneficial effects of MSCs in liver injury. This includes the reduction of cell death and oxidative stress, improvement of hepatocyte function, induction of immunomodulatory effects, and mitigation of cytokine storm. Nevertheless, MSC-EVs face challenges regarding the necessity of defining consistent isolation methods, optimizing MSCs culture conditions, and establishing quality control measures for EV characterization and functional assessment. By establishing standardized protocols, guidelines, and affordable cost mass production, clinicians and researchers will have a solid foundation to conduct further studies, validate the therapeutic efficacy of MSC-EVs, and ultimately pave the way for their clinical implementation in acute liver injury.
- Published
- 2024
- Full Text
- View/download PDF
42. Med1 inhibits ferroptosis and alleviates liver injury in acute liver failure via Nrf2 activation
- Author
-
Zi-Ying Lei, Zhi-Hui Li, Deng-Na Lin, Jing Cao, Jun-Feng Chen, Shi-Bo Meng, Jia-Lei Wang, Jing Liu, Jing Zhang, and Bing-Liang Lin
- Subjects
Acute liver failure ,Ferroptosis ,Mediator complex subunit 1 ,Nuclear factor erythroid 2-related factor 2 ,Heme oxygenase-1 ,NAD(P)H quinone oxidoreductase 1 ,Biotechnology ,TP248.13-248.65 ,Biology (General) ,QH301-705.5 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Extensive hepatocyte mortality and the absence of specific medical therapy significantly contribute to the unfavorable prognosis of acute liver failure (ALF). Ferroptosis is a crucial form of cell death involved in ALF. In this study, we aimed to determine the impact of Mediator complex subunit 1 (Med1) on ferroptosis and its potential hepatoprotective effects in ALF. Results Med1 expression is diminished in the liver of lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced ALF mice, as well as in hepatocytes damaged by H2O2 or TNF-α/D-GalN in vitro. Med1 overexpression mitigates liver injury and decreases the mortality rate of ALF mice by ferroptosis inhibition. The mechanism by which Med1 inhibits erastin-induced ferroptosis in hepatocytes involves the upregulation of nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream antioxidant genes heme oxygenase-1 (HO-1), glutamate cysteine ligase catalytic (GCLC), and NAD(P)H quinone oxidoreductase 1 (NQO1). Furthermore, Med1 overexpression suppresses the transcription of proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the liver of mice with LPS/D-GalN-induced ALF. Conclusion Overall, our research findings indicate that Med1 suppresses ferroptosis and alleviates liver injury in LPS/D-GalN-induced ALF through the activation of Nrf2. These findings substantiate the therapeutic viability of targeting the Med1-Nrf2 axis as a means of treating individuals afflicted with ALF. Graphical Abstract
- Published
- 2024
- Full Text
- View/download PDF
43. Early onset and liver failure indicating poor prognosis of infant liver failure syndrome type 1.
- Author
-
Li, Shu-Yuan, Feng, Jia-Yan, Li, Zhong-Die, and Liu, Teng
- Subjects
- *
LIVER failure , *FETAL growth retardation , *PROGNOSIS , *INFANTS , *SYMPTOMS - Abstract
Background: Infantile liver failure syndrome type 1 (ILFS1, OMIM #615,438), caused by leucyl-tRNA synthase 1 (LARS1, OMIM *151,350) deficiency, is a rare autosomal-recessive disorder. The clinical manifestations, molecular-genetic features, and prognosis of LARS1 disease remain largely elusive. Methods: Three new instances of ILFS1 with confirmed variants in LARS1, encoding LARS1, were identified. Disease characteristics were summarized together with those of 33 reported cases. Kaplan-Meier analysis was performed to assess prognostic factors in ILFS1 patients. Results: The 3 new ILFS1 patients harbored 6 novel variants in LARS1. Among the 36 known patients, 12 died or underwent liver transplantation. The main clinical features of ILFS1 were intrauterine growth restriction (31/32 patients in whom this finding was specifically described), failure to thrive (30/31), hypoalbuminemia (32/32), microcytic anemia (32/33), acute liver failure (24/34), neurodevelopmental delay (25/30), seizures (22/29), and muscular hypotonia (13/27). No significant correlations were observed between genotype and either presence of liver failure or clinical severity of disease. Kaplan-Meier analysis indicated that age of onset < 3mo (p = 0.0015, hazard ratio = 12.29, 95% confidence interval [CI] = 3.74–40.3), like liver failure (p = 0.0343, hazard ratio = 6.57, 95% CI = 1.96-22.0), conferred poor prognosis. Conclusions: Early age of presentation, like liver failure, confers poor prognosis in ILFS1. Genotype-phenotype correlations remain to be established. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Epstein Barr Virus-Related Acute Liver Failure and Hemophagocytosis in an Immunocompetent Individual: An Autopsy Report.
- Author
-
Mitra, Suvradeep, Hanumanthappa, Mohan Kumar, Sarkar, Subhabrata, Bhalla, Ashish, Minz, Ranjana, and Ratho, Radha Kanta
- Subjects
- *
LIVER failure , *FEVER , *AUTOPSY , *MONONUCLEOSIS , *BONE marrow , *PULMONARY fibrosis , *POLYMERASE chain reaction - Abstract
Epstein-Barr virus (EBV) is a nonhepatotropic virus. It causes mild self-limiting illness characterized by fever, oral ulcer, diarrhea, lymphadenopathy, and hepatosplenomegaly. Rarely it causes acute liver failure (ALF). EBV-related ALF (EBV-ALF) accounts for 0.2% of all ALF cases. The prognosis of EBV-ALF is dismal, and it can affect both immunocompromised and immunocompetent individuals. We performed a partial autopsy on a 30-year-old immunocompetent individual with infectious mononucleosis and ALF. The autopsy showed characteristic histomorphology of EBV-ALF in the form of centrizonal confluent hepatocytic necrosis, portal mixed inflammatory infiltrate, sinusoidal lymphocytosis, numerous hemophagocytic figures, and tissue Epstein-Barr encoded RNA-in situ hybridization (EBER-ISH) positivity. Extensive hemophagocytosis was noted in the liver, spleen, lymph node, and bone marrow. Other features include T-zone expansion of lymph nodes and spleen, interstitial pneumonia pattern in the lungs, and exanthematous skin changes. EBV-DNA polymerase chain reaction from the postmortem blood sample yielded 70,200 copies/µL. The index case highlights the uncommon occurrence of EBV-ALF, its histomorphological features, and its putative pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. The thrombopoietin mimetic JNJ-26366821 reduces the late injury and accelerates the onset of liver recovery after acetaminophen-induced liver injury in mice.
- Author
-
Adelusi, Olamide B., Akakpo, Jephte Y., Eichenbaum, Gary, Sadaff, Ejaz, Ramachandran, Anup, and Jaeschke, Hartmut
- Subjects
- *
ACETAMINOPHEN , *THROMBOPOIETIN , *LIVER injuries , *THROMBOPOIETIN receptors , *LIVER , *DRUG therapy , *AMINO acid sequence - Abstract
Acetaminophen (APAP)-induced hepatotoxicity is comprised of an injury and recovery phase. While pharmacological interventions, such as N-acetylcysteine (NAC) and 4-methylpyrazole (4-MP), prevent injury there are no therapeutics that promote recovery. JNJ-26366821 (TPOm) is a novel thrombopoietin mimetic peptide with no sequence homology to endogenous thrombopoietin (TPO). Endogenous thrombopoietin is produced by hepatocytes and the TPO receptor is present on liver sinusoidal endothelial cells in addition to megakaryocytes and platelets, and we hypothesize that TPOm activity at the TPO receptor in the liver provides a beneficial effect following liver injury. Therefore, we evaluated the extent to which TPOm, NAC or 4-MP can provide a protective and regenerative effect in the liver when administered 2 h after an APAP overdose of 300 mg/kg in fasted male C57BL/6J mice. TPOm did not affect protein adducts, oxidant stress, DNA fragmentation and hepatic necrosis up to 12 h after APAP. In contrast, TPOm treatment was beneficial at 24 h, i.e., all injury parameters were reduced by 42–48%. Importantly, TPOm enhanced proliferation by 100% as indicated by PCNA-positive hepatocytes around the area of necrosis. When TPOm treatment was delayed by 6 h, there was no effect on the injury, but a proliferative effect was still evident. In contrast, 4MP and NAC treated at 2 h after APAP significantly attenuated all injury parameters at 24 h but failed to enhance hepatocyte proliferation. Thus, TPOm arrests the progression of liver injury by 24 h after APAP and accelerates the onset of the proliferative response which is essential for liver recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Ethanol Extract of the Microalga Phaeodactylum tricornutum Shows Hepatoprotective Effects against Acetaminophen-Induced Acute Liver Injury in Mice.
- Author
-
Kim, Dae Yoon, Park, Hui Jin, Eom, Jae-In, Han, Cheol-Ho, Pan, Cheol-Ho, and Lee, Jae Kwon
- Subjects
- *
PHAEODACTYLUM tricornutum , *ETHANOL , *LIVER injuries , *LIVER failure , *BLOOD coagulation - Abstract
Acute liver failure is an infrequent yet fatal condition marked by rapid liver function decline, leading to abnormalities in blood clotting and cognitive impairment among individuals without prior liver ailments. The primary reasons for liver failure are infection with hepatitis virus or overdose of certain medicines, such as acetaminophen. Phaeodactylum tricornutum (PT), a type of microalgae known as a diatom species, has been reported to contain an active ingredient with anti-inflammatory and anti-obesity effects. In this study, we evaluated the preventive and therapeutic activities of PT extract in acute liver failure. To achieve our purpose, we used two different acute liver failure models: acetaminophen- and D-GalN/LPS-induced acute liver failure. PT extract showed protective activity against acetaminophen-induced acute liver failure through attenuation of the inflammatory response. However, we failed to demonstrate the protective effects of PT against acute liver injury in the D-GalN/LPS model. Although the PT extract did not show protective activity against two different acute liver failure animal models, this study clearly demonstrates the importance of considering the differences among animal models when selecting an acute liver failure model for evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Mesenchymal Stem Cells Alleviate Acute Liver Failure through Regulating Hepatocyte Apoptosis and Macrophage Polarization.
- Author
-
Yachao Tao, Yonghong Wang, Menglan Wang, Hong Tang, and Enqiang Chen
- Subjects
LIVER cells ,SOMATIC cells ,CELL analysis ,KUPFFER cells ,LIFE sciences ,ISOTHIOCYANATES ,MACROPHAGE inflammatory proteins - Published
- 2024
- Full Text
- View/download PDF
48. Intravital observation of high‐scattering and dense‐labeling hepatic tissues using multi‐photon fluorescence microscopy.
- Author
-
Chen, Runze, Peng, Shiyi, Xia, Qiming, Wu, Tianxiang, Zheng, Junyan, Qin, Haiyan, and Qian, Jun
- Abstract
Achieving high‐resolution and large‐depth microscopic imaging in vivo under conditions characterized by high‐scattering and dense‐labeling, as commonly encountered in the liver, poses a formidable challenge. Here, through the optimization of multi‐photon fluorescence excitation window, tailored to the unique optical properties of the liver, intravital microscopic imaging of hepatocytes and hepatic blood vessels with high spatial resolution was attained. It's worth noting that resolution degradation caused by tissue scattering of excitation light was mitigated by accounting for moderate tissue self‐absorption. Leveraging high‐quality multi‐photon fluorescence microscopy, we discerned structural and functional alterations in hepatocytes during drug‐induced acute liver failure. Furthermore, a reduction in indocyanine green metabolism rates associated with acute liver failure was observed using NIR‐II fluorescence macroscopic imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Whole‐exome sequencing for genetic diagnosis of idiopathic liver injury in children.
- Author
-
Lülecioğlu, Aysima Atılgan, Yazıcı, Yılmaz Yücehan, Baran, Alperen, Warasnhe, Khaled, Beyaz, Şengül, Aytekin, Caner, Özçay, Figen, Aydemir, Yusuf, Barış, Zeren, and Belkaya, Serkan
- Subjects
IDIOPATHIC diseases ,GENETIC disorder diagnosis ,LIVER injuries ,GENETIC disorders ,DISEASE susceptibility - Abstract
Genome‐wide approaches, such as whole‐exome sequencing (WES), are widely used to decipher the genetic mechanisms underlying inter‐individual variability in disease susceptibility. We aimed to dissect inborn monogenic determinants of idiopathic liver injury in otherwise healthy children. We thus performed WES for 20 patients presented with paediatric‐onset recurrent elevated transaminases (rELT) or acute liver failure (ALF) of unknown aetiology. A stringent variant screening was undertaken on a manually‐curated panel of 380 genes predisposing to inherited human diseases with hepatobiliary involvement in the OMIM database. We identified rare nonsynonymous variants in nine genes in six patients (five rELT and one ALF). We next performed a case‐level evaluation to assess the causal concordance between the gene mutated and clinical symptoms of the affected patient. A genetic diagnosis was confirmed in four rELT patients (40%), among whom two carried novel mutations in ACOX2 or PYGL, and two had previously‐reported morbid variants in ABCB4 or PHKA2. We also detected rare variants with uncertain clinical significance in CDAN1, JAG1, PCK2, SLC27A5 or VPS33B in rELT or ALF patients. In conclusion, implementation of WES improves diagnostic yield and enables precision management in paediatric cases of liver injury with unknown aetiology, in particular recurrent hypertransaminasemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. First Application of a Mixed Porcine–Human Repopulated Bioengineered Liver in a Preclinical Model of Post-Resection Liver Failure.
- Author
-
Felgendreff, Philipp, Hosseiniasl, Seyed Mohammad, Minshew, Anna, Amiot, Bruce P., Wilken, Silvana, Ahmadzada, Boyukkhanim, Huebert, Robert C., Sakrikar, Nidhi Jalan, Engles, Noah G., Halsten, Peggy, Mariakis, Kendra, Barry, John, Riesgraf, Shawn, Fecteau, Chris, Ross, Jeffrey J., and Nyberg, Scott L.
- Subjects
LIVER failure ,METABOLIC detoxification ,METABOLIC clearance rate ,LIVER ,ANIMAL models in research ,HEMATOCRIT ,LIVER histology - Abstract
In this study, a mixed porcine–human bioengineered liver (MPH-BEL) was used in a preclinical setup of extracorporeal liver support devices as a treatment for a model of post-resection liver failure (PRLF). The potential for human clinical application is further illustrated by comparing the functional capacity of MPH-BEL grafts as assessed using this porcine PRLF model with fully human (FH-BEL) grafts which were perfused and assessed in vitro. BEL grafts were produced by reseeding liver scaffolds with HUVEC and primary porcine hepatocytes (MPH-BEL) or primary human hepatocytes (FH-BEL). PRLF was induced by performing an 85% liver resection in domestic white pigs and randomized into the following three groups 24 h after resection: standard medical therapy (SMT) alone, SMT + extracorporeal circuit (ECC), and SMT + MPH-BEL. The detoxification and metabolic functions of the MPH-BEL grafts were compared to FH-BEL grafts which were perfused in vitro. During the 24 h treatment interval, INR values normalized within 18 h in the MPH-BEL therapy group and urea synthesis increased as compared to the SMT and SMT + ECC control groups. The MPH-BEL treatment was associated with more rapid decline in hematocrit and platelet count compared to both control groups. Histological analysis demonstrated platelet sequestration in the MPH-BEL grafts, possibly related to immune activation. Significantly higher rates of ammonia clearance and metabolic function were observed in the FH-BEL grafts perfused in vitro than in the MPH-BEL grafts. The MPH-BEL treatment was associated with improved markers of liver function in PRLF. Further improvement in liver function in the BEL grafts was observed by seeding the biomatrix with human hepatocytes. Methods to reduce platelet sequestration within BEL grafts is an area of ongoing research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.